EGFR and non-small cell lung carcinoma: The anilino-quinazoline derivative BIBW 2992 (Afatinib, Gilotrif®), is an oral, highly specific, irreversible panErbB family (EGFR, HER2neu, HER4) receptor TKI already approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of non-small-cell lung cancer (NSCLC) [13].